Ilyang Pharm
Ilyang Pharmaceutical Co.,Ltd operates as a pharmaceutical company primarily in South Korea. The company offers anticancer, circulatory system, endocrine/metabolism, cheonjiyang, female hormone, urinary system, ophthalmology, liver disease, anti-inflammatory analgesic, digestive system, dermatology, respiratory system, nutrient infusion, and neurology medicines. It also provides antibiotics, anti… Read more
Market Cap & Net Worth: Ilyang Pharm (007570)
Ilyang Pharm (KO:007570) has a market capitalization of $159.76 Million (₩233.92 Billion) as of March 18, 2026. Listed on the KO stock exchange, this Korea-based company holds position #17712 globally and #606 in its home market, demonstrating a 5.24% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ilyang Pharm's stock price ₩13050.00 by its total outstanding shares 17924965 (17.92 Million).
Ilyang Pharm Market Cap History: 2015 to 2025
Ilyang Pharm's market capitalization history from 2015 to 2025. Data shows change from $585.28 Million to $159.76 Million (-12.13% CAGR).
Ilyang Pharm Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ilyang Pharm's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Ilyang Pharm's market cap is 0.00 times its annual revenue
1.01x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.01x
Ilyang Pharm's market cap is 0.01 times its annual earnings
10.29x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $585.28 Million | $239.26 Billion | $4.41 Billion | 0.00x | 0.13x |
| 2016 | $498.70 Million | $261.61 Billion | $5.91 Billion | 0.00x | 0.08x |
| 2017 | $461.58 Million | $269.81 Billion | $6.26 Billion | 0.00x | 0.07x |
| 2018 | $329.27 Million | $300.04 Billion | -$4.89 Billion | 0.00x | N/A |
| 2019 | $271.48 Million | $324.57 Billion | $9.98 Billion | 0.00x | 0.03x |
| 2020 | $793.75 Million | $343.33 Billion | $10.88 Billion | 0.00x | 0.07x |
| 2021 | $340.82 Million | $371.35 Billion | $14.38 Billion | 0.00x | 0.02x |
| 2022 | $236.89 Million | $383.81 Billion | $19.24 Billion | 0.00x | 0.01x |
| 2023 | $191.59 Million | $266.67 Billion | -$2.41 Billion | 0.00x | N/A |
| 2024 | $139.68 Million | $268.86 Billion | $10.26 Billion | 0.00x | 0.01x |
Competitor Companies of 007570 by Market Capitalization
Companies near Ilyang Pharm in the global market cap rankings as of March 18, 2026.
Key companies related to Ilyang Pharm by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Ilyang Pharm Historical Marketcap From 2015 to 2025
Between 2015 and today, Ilyang Pharm's market cap moved from $585.28 Million to $ 159.76 Million, with a yearly change of -12.13%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | ₩159.76 Million | +14.37% |
| 2024 | ₩139.68 Million | -27.09% |
| 2023 | ₩191.59 Million | -19.12% |
| 2022 | ₩236.89 Million | -30.49% |
| 2021 | ₩340.82 Million | -57.06% |
| 2020 | ₩793.75 Million | +192.37% |
| 2019 | ₩271.48 Million | -17.55% |
| 2018 | ₩329.27 Million | -28.66% |
| 2017 | ₩461.58 Million | -7.44% |
| 2016 | ₩498.70 Million | -14.79% |
| 2015 | ₩585.28 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Ilyang Pharm was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $159.76 Million USD |
| MoneyControl | $159.76 Million USD |
| MarketWatch | $159.76 Million USD |
| marketcap.company | $159.76 Million USD |
| Reuters | $159.76 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.